Company ProfilePremium

Tianjin Rianlon Chemical Co., Ltd.

Company Profile Analysis

Ticker: 300596.SZ天津利安隆新材料股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Tianjin Rianlon Chemical Co., Ltd. - Company showcase

Year Founded & Workforce

2003

3,068 Employees

Tianjin Rianlon Chemical Co., Ltd. logo

Tianjin Rianlon Chemical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Tianjin Rianlon Chemical Co., Ltd. Overview

ItemDetailSource
Current legal name天津利安隆新材料股份有限公司 (Tianjin Rianlon New Materials Co., Ltd.)H1 2026 Interim Report
English nameRianlon Corporation (RC)H1 2026 Interim Report
Former name利安隆(天津)化工有限公司 — Rianlon (Tianjin) Chemical Co., Ltd. (2003–2013)H1 2026 Interim Report, Note III
Founding / incorporation date8 August 2003 (S&P profile states 2007 — conflicts with the company's own filing; company filing preferred)H1 2026 Interim Report; StockAnalysis profile
Incorporation jurisdictionPeople's Republic of China (Tianjin, TEDA)FY2024 Annual Report
Unified Social Credit Code911,201,167,522,185,471H1 2026 Interim Report
Registered addressNo. 6 Huangshan Road, Hangu Modern Industrial Zone, TEDA, Tianjin 300480FY2024 Annual Report
Head office20F, Block F, No. 20 Kaihua Road, Huayuan Industrial Zone, Nankai District, Tianjin 300384FY2024 Annual Report
Exchange / tickerShenzhen Stock Exchange, ChiNext — 300596 (short name 利安隆)FY2024 Annual Report
ISINCNE100002MQ2StockAnalysis / SZSE profile
CUSIPNot applicable (no US listing)—
Share capital229,619,667 A-shares, 100% unrestricted as of 30 June 2026H1 2026 Interim Report
Fiscal year end31 DecemberFY2024 Annual Report
Legal representativeFan Xiaopeng (范小鹏) — per H1 2026 report (FY2024 report listed Li Haiping)H1 2026 Interim Report
Chairman & President; actual controllerLi Haiping (李海平); ~25.05% combined indirect stakeH1 2026 Interim Report; Eastmoney/Tianyancha summary (Aug 2026)
AuditorBaker Tilly China (天职国际会计师事务所(特殊普通合伙)); standard unqualified opinions FY2024 (Tianzhi Ye Zi [2025] 14766) and FY2025 (Tianzhi Ye Zi [2026] 20716); auditor changed to Baker Tilly in FY2024 (predecessor auditor not named in sources reviewed)FY2024 AR; FY2025 Audit Report
Employees (latest)3,068 (latest annual report, FY2025)Eastmoney summary citing latest AR, Aug 2026
Market capitalizationCNY 9,031 M (29 Sep 2026; close CNY 39.33 on 30 Sep 2026); EV CNY 11,150 MS&P std. via StockAnalysis
Websitewww.rianlon.com; IR e-mail sec@rianlon.com; tel. +86 22 8371 8775FY2024 AR
MetricFY2023FY2024FY2025
Total employees (headcount)3,2383,1533,068
R&D personnel442445—

Note: FY2023 total headcount is derived (442 R&D staff ÷ 13.65% R&D share, FY2024 AR); FY2024 is reported (parent 464 + main subsidiaries 2,689, FY2024 AR); FY2025 is per the latest annual report as cited by Eastmoney (Aug 2026). The FY2024 workforce split was: production 1,552; technical 870; administrative 537; sales 132; finance 62; by education 10 PhDs, 144 master's, 907 bachelor's, 2,092 diploma or below. Outsourced labour amounted to 2.70 million hours costing CNY 96.4 M in FY2024.

Rianlon is China's largest producer of polymer anti-aging additives — antioxidants (RIANOX), light stabilizers including UV absorbers and HALS (RIASORB), and customized one-pack blends (U-pack®) — and describes itself as one of only two companies globally offering a full-range anti-aging portfolio, the other implicitly being BASF. Built by a founding team from Tianjin University's chemical engineering faculty, it operates a "dual-base" supply model in which every core product is made at two or more Chinese sites. Since 2022 it has added a second growth engine in lubricant additives through Jinzhou Kangtai, positioned as a domestic substitute for the Western "big four", and incubated life-science building blocks and electronic-grade polyimide via the 2024 acquisition of Korea's IPITECH. FY2025 revenue was CNY 6.02 bn with CNY 497 M net profit. Its strategic pivot is now toward globalized capacity (Johor, Malaysia) and a partnership with Infineum.


What the company does

Rianlon manufactures specialty chemical additives that are dosed in small quantities into large-volume host materials — plastics, coatings, rubber, fibers, adhesives and lubricating oils — to protect them against thermal-oxidative, photo-oxidative and mechanical degradation. The economic logic is "small dosage, large effect": additives are a minor fraction of a customer's bill of materials but determine whether a polymer part or lubricant meets its service-life specification, which creates qualification barriers, long approval cycles and sticky customer relationships (SZSE company profile; FY2024 AR).

Company's own description (paraphrased from H1 2026 Interim Report and FY2024 AR)

The company characterizes itself as a global "chemistry and biotechnology platform" enterprise whose mission is to create a colourful life through chemistry and biology and whose ambition is a century-old Rianlon brand. Management organizes the business into three "life curves": (1) polymer anti-aging additives — described as "the rice in the pot", the cash-generative core whose goal is global top-tier status; (2) lubricant additives — "the grain in the barn", a scale business positioned as a backbone of domestic substitution; and (3) life sciences — "the rice in the field", an R&D-heavy option on the future. A fourth, separately-managed emerging line covers electronic-grade polyimide (PI) and, since late 2025, electronic adhesives. The organization runs on a "headquarters + business division" model in which each division owns R&D, production, supply chain and sales (H1 2026 Interim Report, MD&A).

Independent characterization

Rianlon is best understood as a mid-cap, vertically integrated Chinese specialty-additives producer whose earnings remain ~80% dependent on a cyclical, increasingly commoditized polymer-additive franchise, onto which management has bolted a lower-margin but faster-growing lubricant-additive business and several venture-like options. Its competitive moat rests on (a) breadth of portfolio, (b) multi-site redundancy, (c) cost position in China, and (d) long qualification histories with global polymer majors. Its weaknesses are a balance sheet that has steadily re-levered (total debt CNY 3.76 bn at FY2025 vs. CNY 1.48 bn at FY2021), structurally weak free-cash conversion, and margins well below pre-2023 levels after a domestic price war. The 2026 strategic narrative — Johor capacity, the Infineum alliance and EU/Japanese capacity retreat — is the most important swing factor for re-rating.

Business and revenue model

DimensionCharacterization
Revenue model~100% product sales (B2B industrial chemicals); no subscription/licensing revenue disclosed. "Other business revenue" was CNY 18.3 M in FY2024 (0.32% of revenue)
Sales channelDirect sales 91.68% (CNY 5,214.0 M) and distributors 8.32% (CNY 472.9 M) in FY2024; distribution grew 26.96% YoY (FY2024 AR)
Revenue recognitionPoint-in-time on delivery (domestic) or customs declaration/bill of lading (export) (H1 2026 report, accounting policies)
Value-chain positionMid-stream: buys petrochemical intermediates (alkylphenols, fatty alcohols/ketones, fatty acids/esters, aromatic amines, inorganics) and sells formulated or single-component additives to polymer producers, compounders, coatings makers, lubricant blenders and additive majors
Customer concentrationLow: top-5 customers = 13.51% of FY2024 sales (largest 4.38%); top-5 suppliers = 24.46% of purchases (FY2024 AR)
Customer typesGlobal and Chinese polymer producers and compounders, coatings/adhesive makers, fiber producers, national oil companies (Sinopec, PetroChina), international oil companies and international additive companies (lubricants), biotech/CDMO and IVD reagent makers (life sciences), flexible-display and FPC makers (PI)
End-marketsAutomotive & transportation (incl. NEV), building & construction, agriculture films, electronics & electrical, packaging, textiles, sports & leisure, household goods, renewable energy (PV/EVA film, energy storage), personal care, healthcare, fuels & lubricants (S&P business description; FY2024 AR)

Key raw-material exposures (FY2024 AR)

Raw material categoryShare of total purchases FY2024 (%)H1 2024 avg price (CNY/kg)H2 2024 avg price (CNY/kg)
Alkylphenols19.2512.0111.95
Fatty ketones/alcohols15.718.407.42
Fatty acids & esters8.8613.3213.73
Inorganic compounds8.663.243.17
Aliphatic hydrocarbons5.2512.8610.72
Aromatic amines3.8213.6812.56
Aliphatic thiols2.6624.6524.41
Coal (CNY/t)1.23537.68480.93

Strategy

Stated strategy (paraphrased themes from FY2024 AR and H1 2026 report)

  1. "2.0 Strategy" (set 2019) with 2028 revenue targets: New Materials Division CNY 10 bn; Lubrication Division CNY 4 bn; Life Sciences Division CNY 1 bn (FY2024 AR). Pursued through "Big 3+1 / Small 3+1" annual targets (definitions not disclosed). A "3.0 plan" for 2028 onward is under preparatory study (H1 2026 report).

  2. Low cost to survive, differentiation to grow: procurement optimization, energy control, lean manufacturing, AI-driven operations; differentiation via high-barrier products (triazine UVAs, low-basicity HALS, water-dispersed and PCR-upgrade additives).

  3. "Dual going-out" of R&D and capacity: Johor, Malaysia as the "bridgehead" of globalization; domestic-plus-overseas supply-chain "dual circulation".

  4. Import substitution of "chokepoint" materials: lubricant additives (domestic standard D1), electronic-grade PI, electronic adhesives.

  5. "Rianlon Basic Law" (H1 2026): five commitments — chemistry-plus-biology dual technology; domestic-plus-international dual markets; innovation as core engine; green/low-carbon transformation; AI-native transformation.

  6. Innovation spend floor: R&D ≥ 4% of revenue annually; new Strategic Development Department for opportunity discovery.

Initiative register (last 24 months)

InitiativeDateDescriptionQuantified target / status
Malaysia R&D & production baseAnnounced 2025; groundbreaking 20 Jan 2026Via Singapore sub; up to USD 300 M; first overseas R&D centrePhase I budget CNY 1,297.85 M; CNY 435.9 M invested, 60% progress (30 Jun 2026); 15.9 kt anti-aging capacity under construction; CNY 1.2 bn guarantee line approved
Infineum strategic framework agreement21 Jan 2026Rianlon component manufacturing integrated into Infineum's global supply network for China/APACExtended 22 Jul 2026 by Infineum–Kangtai distribution collaboration across Southern Asia
Yixing PI base2024–Domestic PI production and R&DBudget CNY 400 M; operation targeted 2027
Stofor electronic adhesives27 Nov 2025CNY 50 M for 25%Associate; −CNY 3.15 M share of loss H1 2026
AI-native transformation2,026"Smart Rianlon Digital Platform", unified data middle-office, AI across R&D/manufacturing/supply chain/marketingNo financial target disclosed
Life sciences commercialization2024–Shift from R&D to dual R&D/market; animal nutrition launchBio-building blocks break-even target FY2026
Personal-care anti-aging2024–Aegis acquisitionsNo target disclosed
ESG/energy2,026Green power at 3 bases; Tianjin steam-saving project; Kaiya direct green-power supply in preparation; reserve projects in distributed PV, biomass CHP7 bases carbon-accounted; 27 product carbon footprints verified
Capital-market programmesJan–Feb 2025"Quality & Return Dual Enhancement" plan; market value management systemCommitment to stable cash dividends; no valuation-enhancement plan disclosed
FinancingJan 2026CNY 800 M sci-tech MTN (2.10%, 3 years)Completed

Medium-term guidance

No numeric annual guidance is published. The only quantified medium-term targets are the 2028 divisional revenue goals (aggregate CNY 15 bn vs. FY2025 actual CNY 6.0 bn), which would require ~35% annual growth from 2026 — implausible organically and best treated as aspirational.

Products & Services

Polymer anti-aging additives (New Materials Division)

Product familyNamed products / chemistriesFunction & specification highlightsTarget customersProduction sitesLatest technical milestones
Primary (hindered phenolic) antioxidantsRIANOX 1010, 1076, 245, 1098, 1035, 1135 (liquid), 2135, 1520, 1726, 1790 (asymmetric), 330 (high-temperature), 1019, 3114, MD-1024 (metal deactivator), MD-697, BBM, CPL, trisphenolRetard oxidative degradation during polymerization, processing and service life; non-organotin catalytic synthesisPolyolefin, ABS, engineering plastics, elastomer, fiber, adhesive producersTianjin, Zhongwei, ZhuhaiTrisphenol process patent application CN119039111A (2024)
Secondary antioxidantsPhosphites incl. hydrolysis-resistant grades, thioesters (412S), alkylated diphenylamines, amide antioxidantsHydroperoxide decomposition; synergy with phenolicsPolymer producers, lubricant and polyol makersTianjin, Zhongwei, ZhuhaiHydrolysis-resistant phosphite patents ZL202011275145.4, ZL202011542259.0
UV absorbersBenzotriazoles (UV-326, 328, 1130, 360), triazines, benzophenones, phenyl benzoates, red-shifted UVA, reactive benzotriazolesAbsorb UV radiation; triazines are highest-performance classCoatings, agriculture film, automotive, PV encapsulantsZhongwei, Kerun, KaiyaThree new triazine UVAs developed in 2024; red-shift UVA US patent US20250026916A1
Hindered amine light stabilizers (HALS)944, 622, NOR-type low-basicity HALS, polymeric HALS, hydroxyl-HALSRadical scavenging; low-basicity grades for acidic environments (agri film, high-end coatings)Coatings, agri film, automotive plasticsKaiya (Hengshui), ChifengOne low-basicity HALS in mass production (2024), two in process design
U-pack® customized blendsLow-melting weathering masterbatches, rubber liquid antioxidants, POM/SBS/PU/PA stabilizer systems, spandex and ES fibre stabilizers, EVA film light-stabilizer packages, cable, C5 resin, polystyrene, wood-plastic, aluminium-silver paste systemsOne-stop formulated solution reduces customer handling and QC costCompounders, OEM-specified applicationsTianjin, Zhongwei, Hengshui, ZhuhaiHigh-performance anti-aging masterbatch in commercial sale; PCR (post-consumer recycled) plastic upgrade packages — three developed, one in mass sales
Water-dispersed additivesUltrafine-milled aqueous antioxidant dispersionsFor emulsion/suspension polymers, waterborne coatings and adhesivesLatex, waterborne coatingsTianjin (5 kt project announced 2022)Three new products at customer evaluation (2025)
Regulatory-replacement productsSVHC-substitute antioxidants/stabilizersCompliance with ECHA/REACH restrictionsEU-facing customers—Two substitution solutions developed
Polymerization inhibitors & intermediates; nylon monomersInhibitors; decanediamine, nylon 1010/1012 salts (Kaiya licence scope)By-product and adjacency chemistryMonomer producersHengshui, Chifeng—
Personal-care anti-agingVia Tianjin Aegis / Aegis Beauty Solutions (HK)Extension of anti-aging chemistry into cosmeticsPersonal-care brands—Management states entry into personal-care anti-aging is in progress (H1 2026 report)

Pricing model: spot and contract B2B pricing; no list prices disclosed. Capacity: designed anti-aging capacity 240.7 kt with 55.65% utilization in FY2024 (FY2024 AR); 242.1 kt in place plus 19.9 kt under construction (Zhongwei 3.5 kt, Kerun 0.5 kt, Malaysia 15.9 kt) per FY2025 AR digest.

Lubricant additives (Lubrication Division — Jinzhou Kangtai)

Product familyContentApplicationsStatus
DetergentsSulfonates, sulfurized alkylphenates (incl. high-TBN, low-free-phenol grades), alkyl salicylatesEngine and marine oilsTwo high-TBN phenates in mass production; two low-free-phenol grades at pilot; four salicylates developed (FY2024 AR)
DispersantsAshless (PIB-succinimide) incl. soot-handling dispersantsHeavy-duty diesel engine oilsSoot dispersant in mass production
Anti-oxidant/anti-wearZDDP, aminic and phenolic antioxidantsEngine and industrial oilsCommercial
Viscosity-index improvers & industrial specialty componentsFull rangeMultigrade oils, industrial lubricantsCommercial
Additive packagesEngine oil (passenger/HDD incl. China D1 standard), marine, industrial (gear, hydraulic), metalworking, grease, shock-absorber fluid, TO-4/UTTO transmission fluids, 2-stroke UAV engine oil, long-drain axle oil (200,000 km)OEM and oil-company blendersFour TO-4/UTTO packages industrialized; UAV 2T oil industrialized; certification of engine/marine/industrial packages ongoing

Capacity: 133 kt with 50.28% utilization (FY2024); plus 30 kt single-component expansion commissioned January 2025, taking capacity to ~163 kt (FY2024 AR; Shenwan Hongyuan May 2026). Kangtai serves over 3,000 customers in 20+ countries and partners with all four international additive majors (FY2024 AR).

Life sciences

LineProductsStatus
Oligonucleotide (small-nucleic-acid drug) raw materials2'-TBDMS-rN, 2'-OMe-rN, 2'-MOE-rN, 2'-F-dN and DNA phosphoramidite (CEPA) monomers; modified nucleosides; GalNAc delivery ligands; UnyLinker solid supportsMonomers in stable production (30–35 kg batches for main series); GalNAc at pilot; UnyLinker at pilot scale; 6 t nucleic-acid monomer pilot plant in Tianjin
mRNA / IVD / sequencing reagentsNTP, dNTP (incl. proprietary hot-start "Thermal-initiated dNTP Mix" launched 2024), ddNTP for nucleic-acid mass spectrometryCommercial on order; ~90 customers developed in 2024; 70+ dNTP/ddNTP customers
Synthetic biologySalidroside, astaxanthin, poly-γ-glutamic acid (trial production and trial sales)Partnerships with Tianjin University, Tianjin University of Science & Technology, CAS Tianjin Institute of Industrial Biotechnology
Animal nutritionNot detailedScenario validation; batch supply to large-scale livestock customers planned H2 2026

Management expects the bio-building-block business to reach break-even in FY2026 (H1 2026 report). Revenue was CNY 3.63 M in FY2024; FY2025 not separately disclosed in sources reviewed.

Electronic materials (PI and adhesives)

ProductDescriptionEnd-useStatus
YPI (PI varnish for flexible OLED substrates)Polyimide precursor coated and cured to replace glass in flexible displaysNotebooks, tablets, TVs, foldablesMass-produced and sold by IPITECH (Korea)
FTPIThermoplastic PI film for adhesive-less 2-layer FCCLSmartphones, wearablesMass-produced in Korea
PTPIHeat-resistant PI tape film for QFN semiconductor packaging (mold-flash protection, residue-free removal)Semiconductor packagingMass-produced in Korea
Electronic adhesivesVia 25% stake in Shenzhen StoforElectronics assemblyEquity-accounted associate

China production base and R&D centre in Yixing (budget CNY 400 M; 20.78% of budget spent, project progress 60% at 30 June 2026) targeted to start in 2027 (H1 2026 report). Management stated at its September 2025 results call that its PI products are used in certain smart-glasses brands (36Kr summary). Rianlon describes partnerships with domestic flexible-circuit and flexible-display leaders with qualification "substantive progress" in H1 2026.

Financial Narrative

Income statement: notes and sources

Sources: S&P std. via StockAnalysis (data updated Aug 2026). CAS-reported basic EPS: FY2022 2.3965, FY2023 1.5786, FY2024 1.8566 (FY2024 AR), consistent with the above.

Balance sheet

Sources: S&P std. via StockAnalysis; short/long debt split derived by summing short-term borrowings, current portion of LTD and leases. CAS asset-liability ratio: FY2023 47.89%, FY2024 48.26%, FY2025 52.61%, H1 2026 52.88% (Eastmoney; H1 2026 report).

H1 2026 balance sheet (CAS, 30 June 2026): total assets CNY 10,886.8 M; cash CNY 1,862.6 M (of which CNY 37.7 M restricted, CNY 102.0 M held offshore); short-term borrowings CNY 2,065.0 M; current portion of non-current liabilities CNY 524.4 M; long-term borrowings CNY 487.7 M (down from CNY 1,099.7 M); bonds payable CNY 806.9 M (new sci-tech MTN); construction in progress CNY 617.9 M (Malaysia CNY 435.9 M, PI CNY 83.1 M); goodwill CNY 636.8 M; parent equity CNY 4,986.1 M.

Goodwill composition (CNY M, unchanged FY2024–H1 2026): Lianlong Kaiya 326.83; Jinzhou Kangtai 172.42; Yixing Chuangju 109.98; Lianlong Kerun 26.62; Tianjin Aegis 0.92. No impairment has been booked; goodwill was a Key Audit Matter in the FY2025 audit report.

Cash flow: notes and sources

Note: S&P's "common dividends paid" line (FY2021 93.9 → FY2025 151.3) appears to include interest paid (CAS line "dividends, profits or interest paid"), so declared dividends are shown instead: FY2021 0.306 × 205.01 M shares and FY2022 0.344 × 229.62 M shares are derived; FY2023 CNY 78.99 M, FY2024 CNY 84.96 M and FY2025 CNY 103.33 M are reported (FY2024 AR; H1 2026 report). H1 2026: operating cash flow +CNY 161.6 M vs −CNY 56.3 M in H1 2025; investing −CNY 265.0 M (overseas project); capex (cash paid for long-term assets) CNY 409.9 M vs CNY 98.5 M.

Ratios

Sources: ROE/ROA/ROIC/liquidity/leverage/turnover from S&P std.; CAS ROE from FY2024 AR. Interest coverage, DSO (year-end AR ÷ revenue × 365), DIO (365 ÷ inventory turnover), DPO (year-end AP ÷ cost of revenue × 365) and CCC are derived; S&P AR may include notes receivable, overstating DSO relative to a trade-only measure. H1 2026 CAS interest coverage 11.41x and EBITDA interest coverage 17.60x (H1 2026 report, bond section).

Commentary on trends, inflections and drivers

FY2021–FY2022 — capacity-led boom. Revenue grew ~39–41% annually as new capacity (Zhongwei, Kaiya, Zhuhai) met a post-pandemic polymer demand surge and Kangtai was consolidated from mid-2022. EBITDA margins held near 17–18% and ROIC exceeded 13%. However, cash conversion was already weak: FY2021 free cash flow was −CNY 203 M because capex (CNY 515 M) and a CNY 706 M receivable build absorbed operating cash.

FY2023 — the inflection. Revenue still grew 9% (Kangtai full-year effect), but S&P gross margin collapsed ~450 bp to 19.1% and net income fell 31% to CNY 362 M. Industry sources describe 2023 as the start of "irrational low-price competition" among Chinese anti-aging producers (Guanyan Tianxia, Dec 2025). Newly commissioned Zhuhai and Chifeng capacity added depreciation (D&A up 37%) before reaching scale. FCF was −CNY 401 M as capex peaked at CNY 574 M.

FY2024–FY2025 — volume-led grind back. Net income recovered 17.6% and 16.5% respectively, driven by volume (anti-aging +6% then +12%; lubricants +23% then +15%), mix improvement in light stabilizers, and a sharp turnaround in Kangtai (FY2025 net profit CNY 96 M, +117%, per Shenwan). Zhuhai swung from a CNY 10.4 M loss (FY2024) to a CNY 32 M profit (FY2025). Pricing remained a headwind: average anti-aging price fell ~7% in FY2025. EBITDA margin recovered to 16.3%, but ROIC (8.1%) remains roughly half the 2021 level.

Balance-sheet drift. Total debt more than doubled from CNY 1.48 bn (FY2021) to CNY 3.76 bn (FY2025), and short-term debt rose to CNY 2.66 bn, reflecting funding of working capital (receivables + inventory up from CNY 1.84 bn to CNY 3.30 bn), M&A and the Malaysia pre-funding. Net debt/EBITDA stayed contained (1.7x) only because cash was also built up (CNY 2.1 bn incl. short-term investments). The cash conversion cycle has lengthened from ~84 to ~150 days (derived), the single most important financial-quality concern.

H1 2026. Revenue CNY 3,389.6 M (+13.17%), net income CNY 297.3 M (+23.24%), recurring net income CNY 293.3 M (+24.12%), despite a CNY 77.1 M financial expense (vs −CNY 1.8 M), largely FX-driven (RMB appreciation). Minority interests absorbed a CNY 12.4 M loss (mainly PI). Gross margin improved in both core segments.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

SegmentFY2023FY2024FY2025

Polymer anti-aging additives (CNY Mn)

4,345.054,594.164,774.00

— of which Antioxidants (CNY Mn)

1,601.581,729.511,920.00

— of which Light stabilizers (CNY Mn)

1,873.902,085.862,075.00

— of which U-pack (CNY Mn)

637.86613.80596.00

Lubricant additives (CNY Mn)

921.711,063.641,207.00

Life sciences (CNY Mn)

0.803.63—

Other incl. other business revenue (CNY Mn)

10.8925.48—

Total revenue (CNY Mn)

5,278.465,686.926,023.00

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Anti-aging revenue YoY growth (%)

—5.733.92

Lubricant revenue YoY growth (%)

—15.4013.51

Anti-aging share of total revenue (%)

82.3280.7879.26

Lubricant share of total revenue (%)

17.4618.7020.04

Anti-aging gross margin (%)

21.5923.7824.36

Lubricant gross margin (%)

11.859.9514.12

Anti-aging gross profit (CNY Mn)

9381,0931,163

Lubricant gross profit (CNY Mn)

109106170

Product Line FY2024 Details

Product line FY2024Revenue (CNY Mn)Cost (CNY Mn)Gross margin (%)Revenue YoY (%)GM change (pp)

Antioxidants

1,729.511,394.3419.387.992.28

Light stabilizers

2,085.861,393.3433.2011.311.25

U-pack

613.80562.498.36-3.771.20

Lubricant additives

1,063.64957.799.9515.40-1.90

Operating Metrics (kt) and Share Price

MetricFY2023FY2024FY2025

Anti-aging sales volume (kt)

116.17123.61138.00

Lubricant sales volume (kt)

47.3358.3267.10

Anti-aging average price (CNY/t)

37,40237,16734,602

Lubricant average price (CNY/t)

19,47418,23717,989

Segment Revenue

SegmentH1 2026 revenue (CNY Mn)YoY (%)H1 2026 GM (%)GM change (pp)Volume (kt)Volume YoY (%)

Polymer anti-aging additives

2,655.6112.6425.862.2177.217.81

Lubricant additives

706.7414.2715.672.1935.84.78

Group Entities

SubsidiaryRoleFY2024 revenue (CNY Mn)FY2024 net profit (CNY Mn)H1 2026 revenue (CNY Mn)H1 2026 net profit (CNY Mn)

Rianlon (Zhongwei) New Materials — Ningxia

Antioxidants/light stabilizers/U-pack; captive heat

1,045.85182.27557.4074.95

Rianlon Technology Co. — Hong Kong

International trading hub

2,195.9859.121,587.4071.09

Lianlong Kaiya (Hebei) — Hengshui

Light stabilizers, intermediates, inhibitors

1,051.79150.33456.7967.13

Lianlong Kerun (Zhejiang) — Changshan

Light stabilizers

254.1526.03139.1721.12

Rianlon (Zhuhai) New Materials

Antioxidants, U-pack, liquid additives

926.53-10.39687.6760.15

Rianlon Supply Chain Management

Domestic trading/logistics

2,217.27-9.271,210.8510.96

Suzhou Rianlon New Materials

East China sales/technical service

0.48-9.05131.75-2.97

Jinzhou Kangtai Lubricant Additives

Lubricant additives

1,083.0244.06740.0660.50

Rianlon (Inner Mongolia) — Chifeng

Light stabilizers and intermediates

225.810.63116.162.01

Yixing Chuangju Electronic Materials (51.18%)

PI holding company; owns IPITECH (Korea)

7.16-17.314.67-13.91

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

3,4454,8435,2785,6876,023

Revenue growth YoY (%)

38.7440.599.007.745.91

Gross profit (CNY Mn)

904.511,1441,0081,1501,274

SG&A (CNY Mn)

230.19294.49322.18397.40404.27

R&D expense (CNY Mn)

151.30208.35233.44247.20253.22

Operating income / EBIT (CNY Mn)

501.61616.79420.33475.66593.17

D&A (CNY Mn)

131.61207.39283.57345.53387.05

EBITDA (CNY Mn)

633.21824.18703.90821.19980.22

Interest expense (CNY Mn)

28.3744.9460.8363.4063.98

FX gain/(loss) (CNY Mn)

-18.26-5.9312.0614.42-10.74

Pre-tax income (CNY Mn)

476.36581.83408.12470.68543.69

Income tax (CNY Mn)

50.1855.9950.6056.4870.24

Effective tax rate (%)

10.539.6212.4012.0012.92

Net income attributable (CNY Mn)

417.59525.72362.49426.32496.56

Basic EPS (CNY)

2.042.401.581.862.16

Diluted EPS (CNY)

2.042.401.581.862.16

Dividend per share declared (CNY)

0.3060.3440.3440.3700.450

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin S&P std. (%)

26.2623.6219.1020.2321.15

Gross margin company-reported CAS (%)

—24.2619.7821.2422.33

Operating (EBIT) margin (%)

14.5612.747.968.369.85

EBITDA margin (%)

18.3817.0213.3314.4416.28

Net margin (%)

12.1210.866.877.508.24

Revenue CAGR from FY2021 (%)

040.5923.7718.1714.99

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

5,5787,5838,2149,13410,517

Cash & equivalents (CNY Mn)

467.88819.36946.751,0681,994

Cash + short-term investments (CNY Mn)

467.88859.371,0401,2302,100

Accounts receivable (CNY Mn)

946.361,1411,4171,6291,937

Inventory (CNY Mn)

893.071,2821,1421,3301,362

Net PP&E (CNY Mn)

2,4273,1663,4453,5813,645

Goodwill (CNY Mn)

353.45525.87525.87636.78636.78

Other intangibles (CNY Mn)

227.57305.37352.83426.54394.41

Short-term debt incl. current LTD and leases (CNY Mn)

741.85688.481,054.011,220.862,656.18

Long-term debt incl. leases (CNY Mn)

735.081,103.061,179.131,477.011,100.68

Total debt (CNY Mn)

1,4771,7922,2332,6983,756

Net debt (CNY Mn)

1,009932.531,1931,4681,656

Total equity incl. minorities (CNY Mn)

2,6263,9284,2804,7264,984

Equity attributable to parent (CNY Mn)

2,5213,8174,1074,4594,827

Working capital (CNY Mn)

288.08959.071,0591,5311,308

Book value per share (CNY)

12.3016.6217.8919.4221.02

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

312.13513.85172.63463.61378.21

Capital expenditure (CNY Mn)

514.98292.83573.67254.67242.36

Free cash flow (CNY Mn)

-202.86221.02-401.04208.94135.85

Change in working capital (CNY Mn)

-326.84-336.17-576.63-437.04-612.96

Cash acquisitions (CNY Mn)

3.19170.170191.850

Cash dividends declared for the fiscal year (CNY Mn)

62.7378.9978.9984.96103.33

Share buybacks (CNY Mn)

00000

Net debt issued/(repaid) (CNY Mn)

624.7543.21663.89136.151,058

Equity issued (CNY Mn)

3.00423.90000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

17.7316.058.719.209.75

Weighted-average ROE, CAS (%)

—16.299.159.95—

ROA (%)

6.685.863.333.433.77

ROIC (%)

13.9813.127.137.178.05

Current ratio (x)

1.131.391.401.541.30

Quick ratio (x)

0.670.820.921.020.94

Debt / equity (x)

0.560.460.520.570.75

Net debt / EBITDA (x)

1.591.131.701.791.69

EBIT interest coverage (x)

17.6813.726.917.509.27

Asset turnover (x)

0.730.740.670.660.61

Inventory turnover (x)

3.533.403.523.673.53

Days sales outstanding (days)

1008698105117

Days inventory outstanding (days)

10310710499103

Days payables outstanding (days)

100109797370

Cash conversion cycle (days)

10384123131150

Revenue History

QuarterRevenue (CNY Mn)Net income attributable (CNY Mn)Source

Q1 2024

1,354.26107.14

FY2024 AR

Q2 2024

1,465.68112.98

FY2024 AR

Q3 2024

1,445.1893.83

FY2024 AR

Q4 2024

1,421.79112.37

FY2024 AR

Q1 2025

1,481108

Derived from Q1 2026 YoY rates (Shenwan)

Q2 2025

1,514133

Derived (H1 2025 total 2,995.0 / 241.3 less Q1)

Q3 2025

1,514151

Derived (FY less H1 less Q4)

Q4 2025

1,514104

Shenwan Hongyuan (May 2026)

Q1 2026

1,592132

Shenwan Hongyuan (May 2026)

Q2 2026

1,797165

Southwest Securities (Aug 2026)

Revenue by Region and Revenue by Region (%)

RegionFY2023FY2024

Domestic China revenue (CNY Mn)

3,328.583,323.46

Overseas revenue (CNY Mn)

1,949.882,363.46

Overseas share of revenue (%)

36.9441.56

Domestic gross margin (%)

15.5516.91

Overseas gross margin (%)

27.0127.33

Region Overview

RegionFY2024 YoY growth (%)

Domestic China

-0.15

Overseas

21.21

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Year-end share price (CNY)

42.5352.2128.5329.8141.80

Year-end market capitalization (CNY Mn)

9,17612,5306,7887,0039,692

Market cap change YoY (%)

13.9536.55-45.833.1838.39

Valuation Multiples

MultipleFY2021FY2022FY2023FY2024FY2025

P/E (x)

21.9723.8418.7316.4319.52

EV/EBITDA (x)

16.2516.4111.6110.7311.71

EV/Sales (x)

2.992.791.551.551.91

P/B (x)

3.493.191.591.481.95

Dividend yield (%)

0.720.661.211.241.08

Analyst Ratings & Targets

BrokerDateRatingTarget price (CNY)2026E revenue (CNY Mn)2026E NI (CNY Mn)2027E NI (CNY Mn)2028E NI (CNY Mn)

Kaiyuan Securities

18 Aug 2026

Buy (maintained)

—7,029657743827

Southwest Securities

31 Aug 2026

Buy (initiation)

57.336,613627742941

Orient Securities

30 Apr 2026

Buy (maintained)

50.16—

EPS 2.64

EPS 3.09

EPS 3.51

Shenwan Hongyuan

4 May 2026

n/d in excerpt

—————

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

DPS (CNY)

0.3060.3440.3440.3700.450

Total cash dividend (CNY Mn)

62.7378.9978.9984.96103.33

Payout of attributable NI (%)

15.015.021.819.920.8

Debt Maturity Profile

Maturity bucket (30 Jun 2026)Amount (CNY Mn)

Short-term borrowings (≤1 yr)

2,065.0

Current portion of non-current liabilities (≤1 yr)

524.4

Long-term bank borrowings (>1 yr)

487.7

Bonds payable (2029)

806.9

Lease liabilities (>1 yr)

0.6

Analyst Conclusions

Management guidance

No numeric FY2026 guidance. Qualitative signals from the H1 2026 report: continued volume growth in both core businesses; bio-building blocks to break even in 2026; animal-nutrition batch supply in H2 2026; Yixing PI capacity in 2027; Malaysia Phase I under construction (60% progress). Long-term 2028 divisional targets (CNY 10 bn / 4 bn / 1 bn) are aspirational.

Consensus expectations

Broker forecasts imply FY2026 revenue of CNY 6.6–7.0 bn (+10–17%) and attributable NI of CNY 627–657 M (+26–32%), with 2027–2028 NI growth of 12–27% annually (Kaiyuan; Southwest; Orient). H1 2026 delivered 49% of the low-end full-year NI forecast, so H2 needs ~CNY 330–360 M — consistent with Q2 2026's CNY 165 M run-rate plus modest growth.

Bull case

  1. Global supply rebalancing: BASF's 2026 price increases and European capacity attrition allow Rianlon to raise anti-aging prices while volume grows ~15%+, restoring EBIT margins toward 12%+ (FY2022 level 12.7%).

  2. Lubricants as a real second engine: Kangtai's FY2025 profit more than doubled; the Infineum alliance and D1 standard could lift utilization of 163 kt capacity and push GM toward the high teens.

  3. Valuation: ~14x 2026E earnings and 1.76x book, below broker peer multiples of 19–21x; a re-rating to 19x on ~CNY 2.8 EPS implies ~CNY 53, near broker targets (CNY 50–57).

Bear case

  1. Cash conversion and leverage: five-year cumulative FCF is negative while debt has risen ~2.5x; Malaysia (≤USD 300 M) and Yixing (CNY 400 M) capex will keep FCF thin through 2027.

  2. Persistent domestic deflation: anti-aging ASP fell 7% in FY2025 and ~4% in H1 2026; if Western price increases fade, margins could stall.

  3. Governance and overhang: combined Chair/President, ~50% pledge ratio at the Group, a potential 3% controller sale, and related-party sourcing may cap multiples.

Key catalysts and monitorables (next 12 months)

  • Q3 2026 results (late October 2026): gross-margin trend, FX losses, receivable build.

  • Execution and timing of the controller's share-sale plan; pledge ratio.

  • Johor Phase I construction progress and commissioning date; customer qualification.

  • Tangible volumes under the Infineum agreement (any disclosure of contract size).

  • BASF/SONGWON pricing actions and Chinese anti-involution enforcement.

  • Kangtai package certifications (D1, marine, industrial).

  • PI qualification wins with display/FPC leaders; Yixing start-up in 2027; Chuangju losses.

  • Goodwill impairment testing at FY2026 year-end.

  • FY2026 dividend (payout trend ~20%).

Analyst verdict

Rianlon is a credible, internationally competitive Chinese specialty-additives champion emerging from a three-year margin trough, but it is not yet a high-quality compounder. The core polymer anti-aging franchise has the breadth, redundancy and export relationships to gain share as Western producers retrench, and 2026 has so far validated that thesis: H1 revenue grew 13% and recurring profit 24%, with margins up in both main segments despite FX headwinds. The lubricant-additive acquisition, initially dilutive to margins, has turned into a genuine second earnings stream, and the January 2026 alliance with Infineum is the most important third-party endorsement in the company's history.

Against this, the financial architecture has deteriorated. Over FY2021–FY2025, Rianlon converted essentially none of its CNY 2.2 bn of cumulative net profit into free cash flow, while total debt rose to CNY 3.8 bn and the cash conversion cycle lengthened materially. The next two years add a heavy capex cycle (Johor and Yixing) and several loss-making options (PI, life sciences, adhesives) whose payoffs are distant. Governance — a combined chair/president, a controller pledging half his holding company's stake and a possible 3% sale — limits the multiple investors will pay.

On balance, the shares at ~CNY 39 (≈14x consensus 2026E, ~10x EV/EBITDA, 1.8x book) discount a meaningful part of the risk while embedding modest expectations for the pricing upturn. The thesis would break on renewed domestic price declines, slippage in Malaysia, or evidence that working-capital growth reflects deteriorating customer credit rather than export mix. Monitor Q3 2026 cash flow closely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / key datesBackgroundAge (FY2024 AR)FY2024 total pre-tax compensation (CNY 10k)

Li Haiping (李海平) "Henry Li"

Chairman (since 2003); President (since Jul 2022); actual controller; re-elected chairman 13 Jun 2025

2003–

Graduate degree, chemical engineering; Tianjin University faculty 1986–2013; ran Tianda Tianhai and Rianlon (Tianjin) Industrial; heads Rianlon Technology Group and Rianlon International

62121.28

Fan Xiaopeng (范小鹏)

Director; legal representative (per H1 2026 report); Technical Director, New Materials Division

Joined 2010; employee supervisor 2018–2025

PhD, chemical engineering; former R&D manager and QC director; chairman of Rianlon (Zhongwei)

4375.15

Sun Chunguang (孙春光)

Vice President

GM 2003–Jul 2022; VP since Jul 2022

Graduate, senior engineer; Tianjin University faculty; chairman of Zhuhai, Aurif, Aolif

63113.35

Xie Jintao (谢金桃)

VP (finance), Board Secretary

Joined 1998; board secretary since Mar 2021

Bachelor's, accounting; former CFO

5089.25

Yan Wenjia (阎文嘉)

CFO and chief accounting officer

Since 23 Aug 2023

Senior accountant; ex-CFO Tianjin Changrong Technology equipment segment, ex-CFO/board secretary TCL Huanxin Semiconductor

4470.03

Ye Qiang (叶强)

Vice President

VP since 13 Jun 2025 (earlier VP 2015–2022, supervisor 2022–2025)

Chemical machinery; ex-Fushun Petrochemical, Shanghai Albemarle, SI Group (Shanghai)

56117.36

Ding Huan (丁欢)

Employee-representative director; audit and nomination committee member

Since 13 Jun 2025 (supervisory board chair 2022–2025)

Foreign languages; strategic cooperation director

41108.46

Bi Hongyan (毕红艳)

Director (status on 5th board n/d)

Joined 2003

Sales; China marketing director; GM of Supply Chain subsidiary

49100.81

Bi Zuopeng (毕作鹏)

Director, 4th board; Kangtai director & manager

2018–2025 (5th board status n/d)

Tianjin University faculty

6297.29

Sun Aitian (孙艾田)

Director & VP, 4th board; executive partner of Juxinlong (ESOP vehicle)

2018–2025 (5th board status n/d)

Tianjin University MBA

60114.28

Han Borui (韩伯睿)

Director & VP, 4th board (departed; locked shares released 12 Jan 2026 as "departed executive")

2019–2025

Ex-GM Lianlong Kaiya

63121.97

Governance Overview

ItemFY2024 (4th board)5th board (from 13 Jun 2025)

Board size

11 (7 non-independent, 4 independent)

—

Independent directors

Wei Lixing (lubricants industry veteran), Li Hongmei (Central South University accounting academic; audit chair), Hou Weiman (lawyer, Hairun Tianrui; remuneration chair), He Yongjun (Beiyang Haitang VC; nomination chair)

—

Committees

Strategy; Remuneration & Appraisal; Nomination; Audit & Risk Control

Strategy committee chaired by Li Haiping; audit and nomination committees include employee director Ding Huan

Supervisory board

3 members (Ding Huan chair, Ye Qiang, Fan Xiaopeng)

Apparently abolished (former supervisors now director/VP), consistent with 2024 Company Law reforms — not confirmed by an announcement reviewed

Chair/CEO separation

No — Li Haiping is both Chairman and President

No

Board meetings FY2024

6, all directors attended in person

—

Major Shareholders

RankShareholderTypeSharesStake (%)Pledged shares
1

Tianjin Rianlon Technology Group Co., Ltd.

Controlling shareholder (Li Haiping)

32,461,29014.1413,237,100
2

Rianlon International Group Ltd.

Controlling shareholder, offshore, concert party

25,059,24010.910
3

Tianjin Juxinlong Equity Investment Fund LP

Employee/management vehicle (Sun Aitian GP)

15,784,4096.871,330,000
4

Tianjin Shengjinlong Enterprise Management LP

Employee/management vehicle (Xie Jintao GP)

6,244,5562.720
5

Han Borui

Individual (ex-director)

6,069,5762.640
6

Bank of Communications – Penghua China 50 Fund

Mutual fund

5,561,7992.420
7

Hong Kong Securities Clearing Co.

Northbound Stock Connect

5,279,3642.300
8

Han Houyi

Individual (Kaiya vendor)

4,156,8001.810
9

Sequoia Jincheng (Xiamen) Equity Investment LP

PE

3,339,7671.450
10

Han Qian

Individual (Kangtai vendor)

1,998,9900.870

Competitive Landscape

Competitors by Segment

SegmentCompetitorCountryPositioning vs. Rianlon

Polymer anti-aging

BASF (Irganox/Tinuvin/Chimassorb)

Germany

Global leader and price-setter; only other full-range supplier; raised prices twice since Mar 2026

Polymer anti-aging

SONGWON Industrial

Korea

Self-described #2 polymer stabilizer producer globally; FY2025 sales KRW 1,039.2 bn, GM 13.7%

Polymer anti-aging

SI Group

USA

Antioxidants/phosphites

Polymer anti-aging

Clariant

Switzerland

Additives (HALS, Hostavin)

Polymer anti-aging

ADEKA

Japan

Antioxidants, nucleators

Polymer anti-aging

Everspring Chemical

Taiwan

UVAs/HALS

Polymer anti-aging

Suqian Unitech (宿迁联盛)

China

HALS/antioxidants; cited as a domestic price-war participant

Polymer anti-aging

Yingkou Fengguang (风光股份)

China

Phenolic and phosphite antioxidants; FY2025 revenue CNY 1,141 M, net loss CNY 48.6 M

Lubricant additives

Lubrizol, Infineum, Chevron Oronite, Afton (NewMarket)

US/UK

~80–85% global share; Infineum now a partner

Lubricant additives

Richful Advanced Materials (瑞丰新材)

China

Largest listed domestic lubricant-additive peer; 9M2024 revenue CNY 2,301 M, NI CNY 500 M, GM 36.1%

Lubricant additives

Wuxi South Petroleum Additives

China

Third scaled private domestic player

Electronic PI

DuPont, UBE, Kaneka, PI Advanced Materials (PIAM)

US/Japan/Korea

80% share of electronic PI film

Peer Comparison FY2025

MetricRianlon FY2025SONGWON FY2025Yingkou Fengguang FY2025Richful (lubricant peer) 9M FY2024

Revenue (native)

CNY 6,023 M

KRW 1,039,162 M

CNY 1,141 M

CNY 2,301 M (9M)

Revenue growth (%)

5.91—13.666.89

Gross margin (%)

22.3313.7—36.08

Net income (native)

CNY 497 M

—

CNY −48.6 M

CNY 500 M (9M)

R&D intensity (%)

4.20———

Company Snapshot

$837.7M

Revenue

3,068

Employees

2003

Founded

SWOT Analysis

Strengths

  • Scale and breadth: FY2025 anti-aging revenue CNY 4,774 M on 138 kt volume with 242 kt capacity — the largest Chinese platform (FY2025 AR digest).
  • Profitable export franchise: Overseas GM 27.33% vs. 16.91% domestic; overseas revenue +21.2% in FY2024 (FY2024 AR).
  • Supply-security model: every core product dual-sourced across six anti-aging bases (H1 2026 report).
  • Low customer concentration: top-5 customers 13.51% of FY2024 sales (FY2024 AR).
  • Proven turnaround of acquisitions: Kangtai FY2025 NI CNY 96 M (+117%) and GM 14.12% (+4.17 pp) (Shenwan).
  • Sustained innovation spend: R&D 4.2–4.4% of revenue for five years; 139 granted invention patents in New Materials (H1 2026).
  • Strong ESG credential: EcoVadis 81, top 5% globally (H1 2026 report).

Weaknesses

  • Margin compression vs. history: EBIT margin 9.85% FY2025 vs. 14.56% FY2021 (S&P).
  • Poor cash conversion: cumulative FY2021–FY2025 FCF −CNY 38 M against cumulative net income CNY 2,229 M (derived from S&P).
  • Lengthening CCC: ~150 days FY2025 vs. ~84 FY2022 (derived).
  • Rising leverage and short-dated funding: total debt CNY 3,756 M; short-term debt CNY 2,656 M at FY2025 (S&P).
  • Low-margin sub-lines: U-pack 8.36% GM; lubricants 9.95% (FY2024).
  • Loss-making ventures: Yixing Chuangju −CNY 17.3 M (FY2024) and −CNY 13.9 M (H1 2026).
  • Governance concentration: combined Chair/President; controller pledges ~50% of the Group's stake.

Opportunities

  • Western capacity retreat: BASF's two price increases since March 2026 (Orient Securities).
  • Infineum partnership could anchor Kangtai and Johor volumes in APAC (Infineum release, Jan 2026).
  • Johor base to bypass tariffs and serve ASEAN/US customers (15.9 kt under construction).
  • China D1 standard favouring domestic lubricant packages (Shenwan).
  • PI import substitution (global PI film market USD 1.3 bn growing 8.7%), Yixing 2027.
  • Anti-involution policy to remove low-end domestic capacity (Shenwan).
  • Bio-building-block break-even expected FY2026 (H1 2026 report).

Threats

  • Trade barriers on ~40% export revenue (risk factor "international policy change", FY2024 AR).
  • FX: H1 2026 financial expense CNY 77.1 M vs. −CNY 1.8 M, mainly FX (H1 2026 report).
  • Goodwill impairment risk on CNY 636.8 M (Key Audit Matter, FY2025 audit).
  • Continued domestic price war: H1 2026 anti-aging implied ASP −4.4% YoY (Kaiyuan).
  • EHS incidents in hazardous-chemical operations (eight entities on mandatory environmental disclosure lists).
  • Share overhang from controller sale plan and pledges (36Kr; Eastmoney).
  • Raw-material spikes linked to oil and geopolitical shocks (H1 2026 report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Apr 2025FY2024 results: revenue CNY 5,686.9 M (+7.74%), NI CNY 426.3 M (+17.61%); dividend CNY 3.70 per 10 sharesRecovery confirmed after 2023 trough
22 Apr 2025Board approves 2025 credit lines up to CNY 10 bn and CNY 1.8 bn new subsidiary guarantees (cumulative CNY 2.8 bn = 62.79% of net assets)Funding capacity for expansion; guarantee to Aurif (liability ratio 100.99%)
22 Apr 20252025 remuneration plan: Li Haiping paid as President onlyGovernance
16 May 2025FY2024 AGM; approves up to CNY 500 M guarantee for Yixing ChuangjuPI funding
13 Jun 20255th board seated; Li Haiping re-elected chairman; Ye Qiang VP; Ding Huan employee directorBoard renewal, 2.0 team elevation
30 Jun 2025China's first domestic diesel-engine-oil standard (D1) released with GB 11122-2025Structural tailwind for domestic lubricant additives
Aug 2025H1 2025 results: revenue CNY 2,995.0 M, NI CNY 241.3 MVolume growth in both segments
11 Sep 2025Online H1 results briefing: management cites PI use in smart glasses; market cap up ~17% YTDNarrative on electronics
Oct 2025Q3 2025: NI up YoY and QoQ (Kaiyuan, 21 Oct 2025)Margin repair continues
24 Oct 2025CNY 198 M guarantee drawn for Yixing ChuangjuPI capex funding
18 Nov 20252026 related-party purchase caps set (Hebei Kaide CNY 150 M; Xinji Yunde CNY 50 M)Governance watch
27 Nov 2025CNY 50 M for 25% of Shenzhen Stofor (electronic adhesives)New electronics adjacency
2025 (date n/d) / Jan 2026 (ann. 2026-001, -005)Decision to establish Singapore subsidiary and invest up to USD 300 M in Malaysian R&D/production baseLargest capex project in company history
12 Jan 20264.93 M shares of departed director/VP Han Borui released from lock-upSupply overhang; 2.0 transition
18 Jan 20263rd ESOP extended term expiresPotential share supply
20 Jan 2026Johor, Malaysia base groundbreakingExecution milestone
21 Jan 2026Strategic framework agreement with InfineumValidation by a global major
22 Jan 2026CNY 800 M 3-year sci-tech MTN at 2.10%Low-cost funding; extends maturities
Mar–Apr 2026Middle East conflict disrupts chemicals; BASF raises antioxidant/light-stabilizer prices twice (Orient Securities)Pricing tailwind for Rianlon
26–28 Apr 2026FY2025 results: revenue CNY 6,023 M (+5.91%), NI CNY 496.6 M (+16.48%); Q1 2026 revenue CNY 1,592 M (+7.5%), NI CNY 132 M (+22.3%); dividend CNY 4.50 per 10 shares; ~CNY 80 M Q4 impairmentsEarnings momentum
28 Apr 20262026 guarantee plan: CNY 2.4 bn new incl. CNY 1.2 bn for Rianlon Malaysia; FX derivatives programme approved; Zhuhai guarantee cap cut to CNY 700 MOverseas funding structure
8 May 2026FY2025 online results briefingIR
22 May 2026Malaysia progress: capital injections of CNY 248.7 M (Singapore) and CNY 252.6 M (Malaysia) completedProject funding
25 May 2026FY2025 AGM approves all resolutionsRoutine
Jun 2026FY2025 dividend paid (CNY 103.3 M)+21.6% DPS
11 May / 8 Jun / 7 Jul 2026Share-pledge transactions by controlling/5%+ shareholdersPledge level rising
22 Jul 2026Infineum–Kangtai distribution collaboration across Southern AsiaPartnership deepening
23 Jul 2026Progress announcement on strategic framework agreementExecution update
18 Aug 2026H1 2026 results: revenue CNY 3,389.6 M (+13.17%), NI CNY 297.3 M (+23.24%); EGM called to amend business scopeStrongest growth since 2022
19–20 Aug 2026Group pledges further 2.99 M shares; cumulative 49.99% of its holdingController liquidity signal
18 Aug – 3 Sep 2026Kaiyuan (Buy, maintained) and Southwest Securities (Buy, initiation, TP CNY 57.33)Sell-side support
Unconfirmed dateControlling shareholder Group plans to sell up to 3% (6.8886 M shares)Overhang

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from CNY 3,445 Mn in FY2021 to CNY 6,023 Mn in FY2025.
Tianjin Rianlon Chemical Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue3,4454,8435,2785,6876,023
Gross profit904.51,1441,0081,1501,274

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Tianjin Rianlon New Materials Co., Ltd., 2026 Interim (H1) Report, SZSE disclosure, 18 Aug 2026 ( and H1 2026 summary. (disc.static.szse.cn)
  2. Rianlon FY2024 Annual Report, cninfo, 22 Apr 2025 ( FY2024 summary, remuneration plan (2025-017), credit/guarantee announcement (2025-018), supervisory board opinion. (static.cninfo.com.cn)
  3. Rianlon FY2025 Audit Report, Baker Tilly China, 28 Apr 2026 ( FY2025 AGM resolution (2026-028). (static.cninfo.com.cn)
  4. Rianlon IR activity record 2025-02 (11 Sep 2025, cninfo).
  5. Pharnexcloud extracts of FY2022, FY2023, FY2024 annual reports; Pharnexcloud broker digest of FY2025 AR.
  6. S&P Global Market Intelligence standardized financials via StockAnalysis.com (income statement, balance sheet, cash flow, ratios, company profile), accessed Oct 2026.
  7. Shenwan Hongyuan Research note on FY2025/Q1 2026 (4 May 2026, via Gelonghui).
  8. Orient Securities note on FY2025 (30 Apr 2026, via Gelonghui).
  9. Kaiyuan Securities company update (18 Aug 2026, Eastmoney PDF).
  10. Southwest Securities H1 2026 initiation (31 Aug 2026, Eastmoney PDF; Stockstar/10jqka summaries).
  11. Soochow Securities notes (Apr and Aug 2020); Dongxing Securities notes (Mar 2022, Oct 2023); Kaiyuan notes (Apr 2022, Aug 2022, Jan 2023); broker note on Kangtai acquisition (2020, Gelonghui).
  12. Infineum press release, 21 Jan 2026 (infineum.com).
  13. Eastmoney / Leida Caijing article on share pledge, 20 Aug 2026.
  14. Sohu Finance governance data (300596); Pharnexcloud personnel profiles.
  15. Sina Finance announcement list and shareholder-meeting pages (300596).
  16. SZSE Releases (szse.io) company page for Rianlon.
  17. 36Kr PitchHub company page (Rianlon).
  18. Techleap/Jiemian item on Stofor investment (Nov 2025).
  19. SONGWON FY2025 results release (4 Mar 2026); Chemical Week article on SONGWON.
  20. Lanjing News on Yingkou Fengguang FY2025 results (Apr 2026); China Securities Journal on Fengguang Q3 2025.
  21. Jiemian on Richful Q3 2024 results (Oct 2024).
  22. Guanyan Tianxia (chinabaogao.com) anti-aging additive industry report (Dec 2025).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.